IIM
SPRY icon

INTECH Investment Management’s ARS Pharmaceuticals SPRY Stock Holding History

INTECH Investment Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
14,833
+1,584
+12% +$13.6K ﹤0.01% 1912
2026
Q1 		$106K Sell
13,249
-9,377
-41% -$89.9K ﹤0.01% 1883
2025
Q4 		$264K Sell
22,626
-8,888
-28% -$86.4K ﹤0.01% 1825
2025
Q3 		$317K Buy
31,514
+5,551
+21% +$79.7K ﹤0.01% 1799
2025
Q2 		$453K Buy
25,963
+3,616
+16% +$52.2K ﹤0.01% 1656
2025
Q1 		$281K Sell
22,347
-8,198
-27% -$98.6K ﹤0.01% 1928
2024
Q4 		$322K Buy
30,545
+14,051
+85% +$197K ﹤0.01% 1802
2024
Q3 		$239K Buy
+16,494
New +$196K ﹤0.01% 1639

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

INTECH Investment Management's SPRY Position: Q2 2026 in Review

INTECH Investment Management increased its ARS Pharmaceuticals (SPRY) stake by 12% in Q2 2026, buying an estimated $13.6K and bringing the position to 14,833 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

INTECH Investment Management first reported a position in SPRY in Q3 2024 and has held it in 8 quarters since. The position peaked at $453K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • INTECH Investment Management held 14,833 shares of ARS Pharmaceuticals worth $119K as of Q2 2026.
  • INTECH Investment Management bought 1,584 ARS Pharmaceuticals shares in Q2 2026, an estimated $13.6K.
  • ARS Pharmaceuticals made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1912 holding.
  • INTECH Investment Management first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • INTECH Investment Management's ARS Pharmaceuticals position peaked at $453K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.